FTC Wants To Keep Fighting Opana Pay-For-Delay Deal
By Chuck Stanley ( July 13, 2018, 6:26 PM EDT) -- The Federal Trade Commission has sought to revive allegations of a pay-for-delay scheme between Endo Pharmaceuticals and generic-drug maker Impax to stall the launch of a generic for opioid medication Opana ER, saying an administrative law judge erred in finding the pro-competitive benefits of the deal outweighed its competitive harms....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.